Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XPACE-1002
- Development stage
- Unknown
- Lead developer
- Xanadu Bio
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intranasal
01
Overview
XPACE-1002 is an intranasal mRNA vaccine booster developed by Xanadu Bio using the proprietary poly(amine-co-ester) (PACE) polymeric nanoparticle delivery platform. Licensed from Yale University, the PACE platform was developed by professors Mark Saltzman and Akiko Iwasaki to overcome the limitations of traditional lipid nanoparticles (LNPs), such as inflammation and poor mucosal penetration. XPACE-1002 delivers mRNA encoding the SARS-CoV-2 spike protein directly to the nasosinus mucosa, aiming to elicit local IgA-mediated mucosal immunity. This approach is designed to prevent local infection and reduce community transmission of COVID-19, addressing a significant gap in current intramuscular vaccines.
- Other names
- intranasal PACE + spike mRNAPACE polyplex spike mRNA vaccine boosterPACE-mRNA
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on XPACE-1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XPACE-1002.